Patent ID: 8877192

Claim:
A method of treating Alzheimer's Disease or amylodosis in a subject comprising administering to a subject a fusion protein, wherein the fusion protein comprises (a) a Receptor for Advanced Glycation Endproducts (RAGE) polypeptide which comprises a first RAGE immunoglobulin domain and a first RAGE interdomain linker linked to a second RAGE immunoglobulin domain and a second RAGE interdomain linker, such that the N-terminal amino acid of the first RAGE interdomain linker is linked to the C-terminal amino acid of the first RAGE immunoglobulin domain, the N-terminal amino acid of the second RAGE immunoglobulin domain is linked to the C-terminal amino acid of the first RAGE interdomain linker, and the N-terminal amino acid of the second RAGE interdomain linker is linked to the C-terminal amino acid of the second RAGE immuno globulin domain, wherein the RAGE polypeptide comprises a RAGE ligand binding site, wherein the second RAGE interdomain linker comprises SEQ ID NO: 22 or a sequence 90% identical thereto, and wherein the C-terminal amino acid of the second RAGE interdomain linker is directly linked to the N-terminal amino acid of (b) a non-RAGE polypeptide comprising at least a portion of a C H 2 domain of an immunoglobulin and a C H 3 domain of an immunoglobulin, and wherein the fusion protein does not include an immunoglobulin Fc hinge region.